Switch to Trimethoprim-Sulfamethoxazole Immediately
This 87-year-old catheterized patient with Stenotrophomonas maltophilia UTI should be switched from Keflex to trimethoprim-sulfamethoxazole (TMP-SMX), which is the first-line therapy for this organism, regardless of reported levofloxacin and ceftazidime susceptibility.
Why TMP-SMX is the Correct Choice
This is a catheter-associated complicated UTI (CA-UTI) in an elderly patient with a multidrug-resistant organism 1. While you mention that "only levofloxacin and ceftazidime will work," the evidence strongly contradicts prioritizing these agents over TMP-SMX for S. maltophilia.
The Evidence Hierarchy
TMP-SMX remains the gold standard:
- Susceptibility rates to TMP-SMX are 93-97% globally 2, 3
- TMP-SMX-based regimens reduce treatment failure (OR 0.29,95% CI 0.11-0.76) compared to other regimens 2
- TMP-SMX is specifically recommended as first-line therapy for S. maltophilia infections 4
Problems with your proposed alternatives:
- Levofloxacin monotherapy shows the highest mortality in comparative studies 5
- Ceftazidime has only 50-55% susceptibility to S. maltophilia 2, 3, making it unreliable as monotherapy
- Fluoroquinolones should be avoided in elderly patients due to adverse effects and should not be used empirically in catheterized urology patients 1, 6
Specific Treatment Algorithm
Step 1: Verify Susceptibility Testing
Confirm that susceptibility testing was performed correctly for S. maltophilia. The organism is intrinsically resistant to Keflex (cephalexin) 7, so continuing it is futile.
Step 2: Dosing Regimen
TMP-SMX 160/800 mg (double-strength) orally twice daily for 7-14 days 1
- Use 14 days in this elderly male to exclude occult prostatitis 1
- Adjust for renal function if creatinine clearance <30 mL/min
Step 3: If TMP-SMX Cannot Be Used
Only if the patient has documented TMP-SMX allergy or resistance:
Combination therapy is superior to monotherapy 5:
- Preferred: Cefoperazone-sulbactam plus TMP-SMX (if sulbactam available) showed lowest mortality 5
- Alternative: Levofloxacin 750 mg daily PLUS ceftazidime 2g IV every 8 hours 8, 9
Step 4: Catheter Management
Replace or remove the catheter 1, 9:
- CA-UTI with S. maltophilia requires catheter removal/replacement for cure
- The biofilm on the catheter serves as a persistent infection source
- This is mandatory per EAU guidelines for complicated UTI management 1
Critical Pitfalls to Avoid
Do not use fluoroquinolone monotherapy: The evidence shows this has the worst outcomes 5. The patient's age (87) also increases risk of fluoroquinolone-associated adverse events including tendon rupture, QT prolongation, and delirium 6.
Do not trust ceftazidime alone: With only 50-55% susceptibility, ceftazidime monotherapy is inadequate 2, 3. If used, it must be combined with another active agent.
Do not continue Keflex: S. maltophilia is intrinsically resistant to first-generation cephalosporins 7. Continuing ineffective therapy increases mortality risk in this high-risk patient.
Risk Factors Present in This Case
This patient has multiple factors associated with poor outcomes 2, 10:
- Advanced age (87 years)
- Indwelling catheter (foreign body)
- Likely prolonged hospitalization
- Prior antibiotic exposure (Keflex)
These factors predict treatment failure and 30-day mortality approaching 49% 2, making optimal antibiotic selection critical.
Monitoring Parameters
- Clinical response within 48-72 hours (fever resolution, improved mental status)
- Repeat urine culture 5-7 days after treatment initiation
- Monitor for TMP-SMX adverse effects: hyperkalemia, renal function, rash
- Assess for sepsis using qSOFA criteria (respiratory rate, mental status, blood pressure) 1
The combination of advanced age, catheterization, and S. maltophilia creates a high-mortality scenario. TMP-SMX with catheter management offers the best survival advantage based on the strongest available evidence 2, 4, 5.